Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6696457 | 0.77 | CHRM5 (0.43) | MAPT | |
| SCHEMBL8191339 | 0.77 | KCNA5 (0.36) | KCNA5 | |
| SCHEMBL305841 | 0.77 | TSHR (0.47) | HTTCYP3A4CYP2C9CYP2C19MAPT | |
| SCHEMBL8190030 | 0.76 | LOXL2 (0.31) | — | |
| SCHEMBL348708 | 0.76 | KCNA5 (0.43) | HTTCHRNB2CHRNA4KCNA5KCNN4 | |
| SCHEMBL26846250 | 0.75 | CHRNB2 (0.50) | HTTCHRNB2CHRNA4KCNA5KCNN4 | |
| SCHEMBL1432726 | 0.75 | NPSR1 (0.51) | HTTCHRNB2CHRNA4KCNA5KCNN4 | |
| SCHEMBL3230643 | 0.73 | CHRNB2 (0.53) | HTTCHRNB2CHRNA4KCNA5KCNN4 | |
| SCHEMBL6671752 | 0.71 | HTT (0.65) | HTTCHRNB2CHRNA4KCNA5KCNN4 | |
| SCHEMBL26846221 | 0.70 | HTT (0.51) | HTTCHRNB2CHRNA4KCNA5KCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223755-B2 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-05-29 | — | — | US | disclosed |
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6140338-A | FOR TREATING ACUTE INFLAMMATORY DISEASES, CHRONIC INFLAMMATORY DISEASES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, CANCER, ISCHEMIC REFLOW DISORDER AND/OR ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL, CO., LTD. (JP) | 2000-10-31 | — | — | US | disclosed |
| EP-0916668-A1 | CHEMOKINE RECEPTOR ANTAGONISTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176704-A1 | Hydroxymorpholinone derivative and medicinal use thereof | CAPN1, OPRM1, CAPN2 | HTT 71/4885CHRNB2 534/4885CHRNA4 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.